Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhabdocell is an inactivated rabies vaccine developed by the Instituto de Tecnologia do Paraná (Tecpar) for use in dogs and cats. It is produced using BHK (Baby Hamster Kidney) cells infected with the adapted PV (Pasteur Virus) strain of the rabies virus through a high-density perfusion cell culture method. This production technique offers improved safety and efficacy compared to older methods using mouse brain tissue. The vaccine stimulates the production of neutralizing antibodies to provide protective immunity against rabies. It is a key component of Brazil's national vaccination campaigns and is licensed by the Ministry of Agriculture, Livestock, and Food Supply (MAPA).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rhabdocell.